Advanced prostate cancer once carried starkly limited prognoses, but aggressive modern treatments like 177lutetium-PSMA-617 and multi-drug therapy combinations are shifting outcomes. Driven by high-profile disclosures and new genetic insights regarding inherited CDK12 mutations, oncologists are re-evaluating early screening, precision radiopharmaceuticals, and aggressive intervention standards for metastatic disease.
How Advanced Prostate Cancer Treatment Has Shifted Over the Past Decade
However, the clinical reality changes dramatically once the cancer spreads outside the prostate gland into the bones or other distant organs.
Treatment protocols for advanced prostate cancer have evolved significantly over the past ten years. Today, medical practice favors early, combined approaches.
Understanding the Markers of Aggressive Disease: Gleason Scores and Bone Metastases
High-profile disclosures, such as updates regarding former President Joe Biden’s diagnosis with an aggressive form of prostate cancer that spread to his bones, have brought renewed public attention to the clinical markers oncologists use to measure disease severity. Three critical details typically guide management strategies: the Gleason score, the location of metastasis, and whether the tumor remains hormone-sensitive.
Pathologists assign a Gleason score from 6 to 10 after examining biopsy samples under a microscope, with higher numbers indicating more abnormal and aggressive tissue. A score of 9 falls into the highest-risk category. When prostate cancer metastasizes, it most commonly targets the bones, particularly the spine, pelvis, and ribs, though it can also reach the lungs or liver.
“The pathologists’ interpretation of President Biden’s cancer (Gleason 9) is that it appears to be highly aggressive. This is not encouraging news.”
Gerald Denis, researcher at the Shipley Prostate Cancer Research Center
While metastatic disease to the bone is generally considered advanced and incurable, effective management can slow its progression for years. Initially, these cancers are hormone-sensitive, meaning they rely on testosterone to fuel growth and still respond to hormone-suppressing therapies. Over time, however, many advanced cancers adapt and become hormone-resistant, requiring oncologists to introduce additional therapeutic modalities.
Expanded Precision Radiotherapy and the Role of Lu-PSMA
Precision medicine has introduced targeted radiopharmaceuticals to the treatment landscape for advanced disease. The FDA expanded the approval of 177lutetium-PSMA-617, also known as Lu-PSMA and marketed as Pluvicto, for patients with metastatic castration-resistant prostate cancer who have already received an androgen receptor pathway inhibitor and are appropriate to delay taxane-based chemotherapy, as outlined by the PCF.
Lu-PSMA functions by binding directly to prostate-specific membrane antigen (PSMA), a protein found on nearly all prostate cancer cells. The attached radioactive lutetium-177 payload then delivers targeted radiation directly to the cancer cell while limiting damage to surrounding healthy tissue. Results from the Phase 3 PSMAfore trial demonstrated that patients treated with Lu-PSMA were 59% less likely to experience disease progression on scans or death compared to those who only underwent a change in their androgen receptor pathway inhibitor medication.
Identifying Rare Inherited CDK12 Mutations in Young Patients
Beyond acquired mutations, recent genomic research has identified entirely new hereditary risk factors linked to aggressive prostate cancer. Researchers at the University of British Columbia published a study in Cancer Discovery identifying that rare inherited mutations in the CDK12 gene can drive aggressive, metastatic prostate cancer in younger men, according to reporting from News-Medical.net.
The international research team analyzed genetic data from over 4,500 people with aggressive prostate cancer, uncovering five unrelated men carrying germline CDK12 mutations who all developed metastatic disease between the ages of 44 and 62. Previously, scientists believed harmful CDK12 alterations occurred strictly within tumor cells spontaneously. By confirming a distinct genetic fingerprint left behind when CDK12 fails, the team provided concrete evidence that these inherited variants directly cause cancer development.
“What’s striking is that every patient we identified with this inherited mutation had already developed metastatic disease by the time they were diagnosed. The opportunity now is to identify these families earlier and give people the chance to benefit from enhanced screening, when there are still curative treatment options.”
Dr. Alexander Wyatt, senior author and associate professor of urologic sciences at the University of British Columbia
This integration could allow clinicians to flag at-risk families early, facilitating proactive surveillance and intervention before advanced metastatic tumors have a chance to form.
Keep reading